

Please type a plus sign (+) inside the



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	(NOT YET ASSIGNED)
		Filing Date	July 5, 2001
		First Named Inventor	Yoichi FUJII
		Group Art Unit	1648
		Examiner Name	U. Winkler
Sheet 2 of 2	Attorney Docket Number	NZK-128-1	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
UW		FUJII, Y., ET AL., "Biological Overview of HIV Accessory Protein Nef," <u>Saibo Kogaku</u> , 1997, pp. 94-99, vol. 16, no. 1	
		LIU ET AL., "Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation", <u>The Journal of biological Chemistry</u> , 1997, pp. 13779-13785, Vol. 272	
		CAWTHON ET AL., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene", <u>Genomics</u> , 1991, pp. 446-460, Vol. 9	
		AHN ET AL., "The structural and functional diversity of dystrophin", <u>Nature Genetics</u> , 1993, pp. 283-291, Vol. 3	
		OKADA, H., ET AL., "Inhibition of HIV-1 Nef induced apoptosis of uninfected human blood cells by serine/threonine protein kinase inhibitors, fasudil hydrochloride and M3", <u>FEBS LETTERS</u> , 2-6-98, PPS. 363-367, Vol. 422, No. 3, XP002115665, Amsterdam, NL	
		LUO T., ET AL., "Infectivity enhancement by immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase", <u>Journal of Virology</u> , 1997, pp. 9524-9530, Vol. 71, No. 12, XP002115666, US	
		ROSSI, F., ET AL., "H ₃ N3 proteasomal subunit as a target for human immunodeficiency virus type 1 Nef protein", <u>Virology</u> , 1997, pp. 33-45, Vol. 237, No. 1, XP002115667, Orlando, US	
		SMITH, B.L., ET AL., "The HIV Nef protein associates with protein kinase C theta", <u>Journal of Biological Chemistry</u> , 1996, pp. 16753-16757, Vol. 271, No. 28, XP002115668, MD, US	
		DE REUCK, ET AL., "A double-blind study of neurotrophin in patients with acute ischemic stroke," <u>Acta Neurol Scand</u> , 1994, pp. 329-335, 89	


Examiner Signature	<i>[Signature]</i>	Date Considered	11/25/02
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside thi




PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	(NOT YET ASSIGNED)
		Filing Date	July 5, 2001
		First Named Inventor	Yoichi FUJII
		Group Art Unit	1648
		Examiner Name	U. Winkler
Sheet 1 of 2	Attorney Docket Number	NZK-128-1	



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
UW		4,816,397		Michael A. BOSS et al.	Mar. 28, 1989	
		4,816,567		Shmuel CABILLY et al.	Mar. 28, 1989	
		5,225,539		Gregory Paul WINTER	July 6, 1993	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number	Kind Code ⁵ (if known)			
UW		EP	0 120 694 B1		Celltech Limited	Oct. 3, 1984	
		EP	0 125 023 B1		Genentech, Inc.	Nov. 14, 1984	
		EP	0 239 400 A2		Gregory Paul WINTER	Sept. 30, 1987	
		WO	86/01533		Celltech Limited	Mar. 13, 1986	
		WO	98 13377		Blomolecular Research Institute Ltd.	Apr. 2, 1998	
		FR	2 720 068		Institut National de la Sante et de la Recherche Medicale	Nov. 24, 1995	
		JP	04360838		Sanyo Kokusaku Pulp Co., Ltd.	Dec. 14, 1992	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/25/02
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.